Literature DB >> 8790020

Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance.

B Eliasson1, M R Taskinen, U Smith.   

Abstract

BACKGROUND: Insulin sensitivity and cardiovascular risk profile were examined in 20 healthy, nonobese, middle-aged men who were long-term users of nicotine-containing chewing gum and in 20 matched control subjects who did not use nicotine. METHODS AND
RESULTS: Long-term use of nicotine-containing chewing gum was associated with insulin resistance and hyperinsulinemia. The degree of insulin sensitivity correlated negatively to the extent of nicotine use measured as plasma cotinine levels.
CONCLUSIONS: These findings suggest that nicotine is the major constituent in cigarette smoke that leads to insulin resistance, metabolic abnormalities associated with the insulin resistance syndrome, and increased cardiovascular morbidity. Thus, the use of nicotine replacement therapy during smoking cessation should be transient and limited.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790020     DOI: 10.1161/01.cir.94.5.878

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Estimating the health consequences of replacing cigarettes with nicotine inhalers.

Authors:  W Sumner
Journal:  Tob Control       Date:  2003-06       Impact factor: 7.552

2.  Obesity Paradox and Smoking Gun: A Mystery of Statistical Confounding?

Authors:  Xi-Yong Yu; Ping Song; Ming-Hui Zou
Journal:  Circ Res       Date:  2018-06-08       Impact factor: 17.367

3.  Assessing the impact of cigarette smoking on β-cell function and risk for type 2 diabetes in a non-diabetic Chinese cohort.

Authors:  Cai Chen; Ya-Qin Tu; Ping Yang; Qi-Lin Yu; Shu Zhang; Fei Xiong; Cong-Yi Wang
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

4.  The effect of smoking cessation pharmacotherapies on pancreatic beta cell function.

Authors:  Amanda K Woynillowicz; Sandeep Raha; Catherine J Nicholson; Alison C Holloway
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-27       Impact factor: 4.219

5.  Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacokinetics and glucodynamics.

Authors:  Alan X Pan; Amparo de la Peña; Kwee P Yeo; Clark Chan; Mei T Loh; Stephen D Wise; Bernard L Silverman; Douglas B Muchmore
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

6.  MicroRNA-191, acting via the IRS-1/Akt signaling pathway, is involved in the hepatic insulin resistance induced by cigarette smoke extract.

Authors:  Qianlei Yang; Yan Cui; Fei Luo; Xinlu Liu; Qiushi Wang; Jun Bai; Faqin Dong; Qian Sun; Lu Lu; Hui Xu; Junchao Xue; Chao Chen; Quanyong Xiang; Qizhan Liu; Qingbi Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-29       Impact factor: 4.223

7.  Cigarette Smoking: An Accessory to the Development of Insulin Resistance.

Authors:  Ashley Artese; Bryant A Stamford; Robert J Moffatt
Journal:  Am J Lifestyle Med       Date:  2017-08-23

8.  E-cigarette use is associated with a self-reported diagnosis of prediabetes in never cigarette smokers: Results from the behavioral risk factor surveillance system survey.

Authors:  Nkiruka C Atuegwu; Mario F Perez; Cheryl Oncken; Erin L Mead; Narinder Maheshwari; Eric M Mortensen
Journal:  Drug Alcohol Depend       Date:  2019-10-28       Impact factor: 4.492

9.  Novel and reversible mechanisms of smoking-induced insulin resistance in humans.

Authors:  Bryan C Bergman; Leigh Perreault; Devon Hunerdosse; Anna Kerege; Mary Playdon; Ali M Samek; Robert H Eckel
Journal:  Diabetes       Date:  2012-09-10       Impact factor: 9.461

10.  Chronic exposure to nicotine enhances insulin sensitivity through α7 nicotinic acetylcholine receptor-STAT3 pathway.

Authors:  Tian-Ying Xu; Ling-Ling Guo; Pei Wang; Jie Song; Ying-Ying Le; Benoit Viollet; Chao-Yu Miao
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.